Abstract
Coronavirus disease 2019 (COVID-19) has resulted in millions of deaths globally. The pandemic has had a severe impact on oncology care and research. Patients with underlying cancer are more vulnerable to contracting COVID-19, and also have a more severe clinical course following the infection. The rollout of COVID-19 vaccines in many parts of the world has raised hopes of controlling the pandemic. In this editorial, the authors outline key characteristics of the currently approved COVID-19 vaccines, provide a brief overview of key emerging issues such as vaccine-induced immune thrombotic thrombocytopenia and SARS-CoV-2 variants of concern, and review the available data related to the efficacy and side effects of vaccinating patients with cancer.
Original language | English |
---|---|
Pages (from-to) | 255-265 |
Number of pages | 11 |
Journal | Oncology and Therapy |
Volume | 9 |
Issue number | 2 |
DOIs | |
Publication status | Published - Dec 2021 |
Keywords
- Cancer
- COVID-19
- Efficacy
- mRNA
- SARS-CoV-2
- Toxicity
- Vaccine
- Viral vector
ASJC Scopus subject areas
- Oncology